• A study published in April 2024 found that semaglutide, the active ingredient in Ozempic and Wegovy, contributed to nearly 25,000 emergency room visits between 2022 and 2023, primarily due to gastrointestinal complications.
• Reports indicate new side effects like 'Ozempic mouth' (facial volume loss and sagging skin) and 'Ozempic feet' (sagging skin on the feet), prompting patients to seek cosmetic treatments.
• Experts recommend doctors counsel patients on potential gastrointestinal side effects and adjust co-prescribed medications to mitigate risks; gradual weight loss and supportive footwear are suggested to reduce 'Ozempic feet'.

The increased use of weight-loss drugs such as Ozempic and Wegovy has led to a rise in reported side effects and emergency room visits. A recent study analyzing national surveillance data highlighted a significant number of hospital visits related to gastrointestinal complications, as well as other adverse reactions. Additionally, emerging reports detail new cosmetic side effects like 'Ozempic mouth' and 'Ozempic feet,' raising concerns about the rapid weight loss associated with these medications and the impact on overall health.

• What: Increased reports of side effects, including gastrointestinal complications, 'Ozempic mouth' (facial volume loss), and 'Ozempic feet' (sagging skin on feet) associated with weight-loss drugs like Ozempic and Wegovy.
• Who: Individuals using semaglutide (Ozempic, Wegovy), scientists from the Centers for Disease Control and Prevention, physicians like Dr. Pieter Cohen and Dr. Mahyar Etminan, cosmetic dermatologists like Dr. Michele Green, and celebrities like Sharon Osbourne, Whoopie Goldberg, and Rebel Wilson.
• When: Study data covers 2022-2023, with the majority of emergency room visits occurring in 2023. Reports on 'Ozempic mouth' and 'Ozempic feet' are emerging in 2024 and 2025.
• Where: United States (national surveillance data collected at dozens of hospitals), Hollywood (celebrity usage and cosmetic treatments).

The rise in emergency room visits and the emergence of cosmetic side effects highlight the potential risks associated with rapid weight loss through drugs like Ozempic and Wegovy. While these medications can be effective for weight management and treating type 2 diabetes and chronic obesity, the potential for severe gastrointestinal issues and other adverse reactions cannot be ignored. The cosmetic effects, such as 'Ozempic mouth' and 'Ozempic feet', further underscore the need for a balanced approach that includes patient counseling, gradual weight loss strategies, and appropriate medical supervision. The differing viewpoints between the manufacturer (highlighting clinical study results) and independent researchers (pointing out real-world adverse events) suggest a need for further research and transparency.

"We found that it’s very infrequent that semaglutide leads to very serious adverse events that would land a patient in the hospital, but that they do occur."

"The adverse events presented [in this study] are not new."

"Many users of Ozempic who I know report noticeable volume loss in the face, which can result in the formation of fine lines, wrinkles, sagging skin, and jowls around the mouth."

"The underlying mechanism is that when fat is lost quickly, the skin’s natural elasticity may not be able to keep up."

The widespread adoption of weight-loss drugs like Ozempic and Wegovy highlights their effectiveness in managing weight and associated health issues, yet simultaneously raises concerns about potential risks that warrant careful consideration. While these medications offer significant benefits, the emergence of side effects, including gastrointestinal distress, dehydration, and even more serious complications such as gallbladder problems, pancreatitis, kidney injury, and vision changes, necessitates vigilant monitoring. Moreover, the rise of cosmetic concerns like "Ozempic mouth" and "Ozempic feet," characterized by sagging skin and volume loss, underscores the complex relationship between rapid weight loss and overall well-being. Additionally, there have been reports of changes in mood and behavior, including worsening depression and suicidal thoughts. The increase in emergency room visits related to these drugs further emphasizes the importance of patient education and appropriate medical supervision. Long-term studies are needed to fully understand the lasting effects and potential risks associated with these medications. Transparent communication between healthcare providers and patients, coupled with ongoing research, is crucial to navigate the benefits and risks of Ozempic and Wegovy effectively, ensuring informed decision-making and promoting patient safety.